GlaxoSmithKline Said Earlier Wednesday that Hal Barron will Leave his position as Chief Scientific Officer in August to Run Start-up Biotech Company; Tony Wood Named New CSO
GlaxoSmithKline plc (GSK) today announced the appointment of Tony Wood as Chief Scientific Officer (CSO) designate. Tony will assume full accountability for Research and Development (R&D) from current CSO, Dr Hal Barron, on 1 August 2022, after which Hal will remain on GSK's Board and become a Non-Executive Director, with additional responsibilities to support R&D.
